冠状动脉粥样硬化形成与中医气虚血瘀病机相关性研究

The Research of Relationship between Coronary Atherosclerosis Formation and Qi Deficiency and Blood Stasis Syndrome

目的观察益气化瘀胶囊预防性治疗冠状动脉粥样硬化,防止或延缓冠心病发生的临床疗效及安全性,探讨冠状动脉粥样硬化形成与中医气虚血瘀病机的相关性。方法240例轻度冠状动脉粥样硬化患者(冠状动脉造影示管腔狭窄<50%)随机分为两组,治疗组120例口服益气化瘀胶囊,每次4粒,每日3次;对照组120例口服辛伐他汀,每次10mg,每日1次。两组均以6个月为1个疗程,观察两个疗程(12个月),然后评估两组疗效,不良反应和毒副反应。结果两组治疗6个月、12个月后胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)与治疗前比较均有统计学意义(P<0.05);但两组治疗后比较差异无统计学意义(P>0.05)。两组治疗6个月后及12个月后常规心电图检测阳性发生率比较无统计学意义(P>0.05);在气虚血瘀证候改善方面,治疗组与对照组治疗12个月后,总有效率分别为89.29%和31.19%,两组比较有统计学意义(P<0.05)。结论益气化瘀胶囊在预防性治疗冠状动脉粥样硬化,防止冠心病发生方面优于小剂量辛伐他汀。气虚血瘀病机是冠状动脉粥样硬化形成与进展的中医最基本病机。

Objective To observe the clinical effect and safety of prevention of coronary atherosclerotic disease and postponing the coronary atherosclerotic heart disease by Yiqihuayu capsule, and then to discuss the relativity between coronary atherosclerosis and traditional Qi deficiency and blood stasis disease. Methods Two hundreds and forty patients （pts） with low - grade coronary heart disease （coronary artery stenosis〈 50%） were randomly divided into two groups： Treatment group （n=120） treated by Yiqihuayu capsule （4 pile,trice a day） and control group （n=120） treated by simvastatin （10 mg,a day）. Results The clinical effect in treatment group and control group was similar in blood lipid intervention （P〉0.05）. There was significant difference in treatment group before and after the treatment （P〈0.05）. The positive rate of exercise test in control group was evidently higher than that in treatment group （P〈0.05）. There was statistical significahce in two groups on improving Qi deficiency and blood stasis symptom （P〈0.05）. Conclusion Effect of Yiqihuayu capsule was superior to that of simvastatin on prevention of coronary atheroscterotic disease. The pathogenesis of Qi deficiency and blood stasis was the most basal traditional Chinese medical pathogenesis in the form and develop of coronary atherosclerosis. There was not evident adverse reaction and toxic and side effects in two groups.